Allogeneic hematopoietic stem-cell transplantation in myelofibrosis: Key messages for clinical practice in the era of Janus kinase 1/2 inhibitors

Piyanuch Kongtim; Uday Popat

doi:10.1200/JOP.2016.014308

Allogeneic hematopoietic stem-cell transplantation in myelofibrosis: Key messages for clinical practice in the era of Janus kinase 1/2 inhibitors

Piyanuch Kongtim, Uday Popat

Stem Cell Transplantation

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	633-634
Number of pages	2
Journal	Journal of oncology practice
Volume	12
Issue number	7
DOIs	https://doi.org/10.1200/JOP.2016.014308
State	Published - Jul 2016

ASJC Scopus subject areas

Oncology
Oncology(nursing)
Health Policy

Access to Document

10.1200/JOP.2016.014308

Cite this

@article{21b75a402ffc4ef38be314d3160a0b81,

title = "Allogeneic hematopoietic stem-cell transplantation in myelofibrosis: Key messages for clinical practice in the era of Janus kinase 1/2 inhibitors",

author = "Piyanuch Kongtim and Uday Popat",

year = "2016",

month = jul,

doi = "10.1200/JOP.2016.014308",

language = "English (US)",

volume = "12",

pages = "633--634",

journal = "Journal of oncology practice",

issn = "1554-7477",

publisher = "American Society of Clinical Oncology",

number = "7",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem-cell transplantation in myelofibrosis

T2 - Key messages for clinical practice in the era of Janus kinase 1/2 inhibitors

AU - Kongtim, Piyanuch

AU - Popat, Uday

PY - 2016/7

Y1 - 2016/7

UR - http://www.scopus.com/inward/record.url?scp=84978906408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978906408&partnerID=8YFLogxK

U2 - 10.1200/JOP.2016.014308

DO - 10.1200/JOP.2016.014308

M3 - Comment/debate

C2 - 27407159

AN - SCOPUS:84978906408

SN - 1554-7477

VL - 12

SP - 633

EP - 634

JO - Journal of oncology practice

JF - Journal of oncology practice

IS - 7

ER -

Allogeneic hematopoietic stem-cell transplantation in myelofibrosis: Key messages for clinical practice in the era of Janus kinase 1/2 inhibitors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this